Azioni Caris Life Sciences, Inc. (CAI) — è una buona azienda?

Azioni Caris Life Sciences, Inc. (CAI) — è una buona azienda? — InspectStocks

Come guadagna

Molecular profiling services97%
Pharma research and development services4%

Le quote di ricavo sono stime per six months ended June 30, 2026, non cifre tratte da un documento depositato.

Compete con

RHHBYFoundation Medicine (a Roche subsidiary)
TEMTempus AI
C
Dimensione
13,8B USD
Margine
-12,5%
GHGuardant Health
B
Dimensione
20,9B USD
Margine
-37,9%
NTRANatera
B
Dimensione
46,8B USD
Margine
-5,7%
GRALGRAIL
D
Dimensione
5,5B USD
Margine
-243,8%
PSNLPersonalis
D
Dimensione
1,7B USD
Margine
-147,7%

Che cosa vende6

MI Profile
A cancer tissue test that examines DNA, RNA, and selected proteins, then gives doctors a report about the tumor that can help guide treatment choices.
Caris Assure
A blood test that examines tumor-related DNA and RNA in the blood and compares them with blood-cell DNA to help distinguish cancer changes from age-related blood-cell changes.
Caris Detect
A blood test designed to look for signs of multiple cancers, including cancers that may not yet have been found through symptoms or other tests.

Mostra altri 3

Caris ChromoSeq
A test of bone marrow or blood samples that examines DNA and RNA to help assess myeloid blood cancers, including acute myeloid leukemia and myelodysplastic syndromes.
Caris MI Clarity
A breast cancer test that examines digitized tissue-slide images and clinical information to estimate the chance of cancer returning at a distance from the original tumor.
FOLFIRSTai
A molecular signature included with certain cancer profiling results that helps doctors assess whether a patient with advanced colorectal cancer may benefit from particular chemotherapy combinations.

Chi lo compra4

Oncologists and other ordering physicians order tests for patients, often through hospitals, cancer centers, or medical groups.
Government and commercial health insurers pay for some patient tests when they cover the test and its use.
Biopharma companies pay for patient profiling, research support, and access to deidentified molecular and clinical data.
Academic cancer centers and researchers use Caris data and collaborate on cancer research.

Su cosa si regge e cosa potrebbe romperlo

Da che cosa dipende l'attività

1Most revenue comes from clinical molecular profiling, particularly tissue-based profiling.
2Clinical testing revenue depends on government and commercial insurers covering tests and setting reimbursement rates; Medicare-covered cases generated 40.0% (six months ended June 30, 2026, high) of molecular profiling services revenue.
3Laboratory work relies on sequencing equipment and supplies from third-party suppliers, including Illumina and Roche.
4The company depends on laboratory capacity, sample transport and handling, and computing systems to process patient samples and deliver results.

Che cosa potrebbe andare storto

1A large share of current revenue comes from tissue-based profiling, so changes in test volumes or physician and patient adoption could affect the business.
2Insurers and government programs decide whether to cover tests and how much to reimburse; limited coverage or lower reimbursement could constrain testing and revenue.
3New and developing tests depend on validation, regulatory requirements, and payer decisions; delays or changes in these areas could prevent or limit their commercial use.

Bilanci completi →

Informazioni su Caris Life Sciences, Inc.

Caris analyzes DNA and RNA from cancer tissue and blood to find molecular features that may help doctors choose treatments. Its tests examine the whole exome—the protein-coding parts of DNA—or the whole transcriptome, and the company uses artificial intelligence (AI) and machine learning (ML) to interpret results. Caris also provides data and research services to drug companies and uses patient samples and data to investigate potential cancer drug targets.

Sede: Irving, Texas
Fondata nel: 2008
Quotata su: Nasdaq
Chiusura dell'esercizio: December 31

Costruito dai documenti depositati da Caris Life Sciences, Inc. presso la Securities and Exchange Commission (SEC), l’autorità di vigilanza statunitense. Le cifre sono quelle dichiarate, con lo storico per azione ricalcolato sulla base azionaria di oggi. Questo descrive un’azienda: non è consulenza finanziaria né una raccomandazione di acquisto o vendita.

Keep exploring

The themes Caris Life Sciences is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

Highest-graded in Biotechnology

Graded A or B and worth $2B or more: A first, then the largest.

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

Come guadagna

Molecular profiling services97%
Pharma research and development services4%

Le quote di ricavo sono stime per six months ended June 30, 2026, non cifre tratte da un documento depositato.

Compete con

RHHBYFoundation Medicine (a Roche subsidiary)
TEMTempus AI
C
Dimensione
13,8B USD
Margine
-12,5%
GHGuardant Health
B
Dimensione
20,9B USD
Margine
-37,9%
NTRANatera
B
Dimensione
46,8B USD
Margine
-5,7%
GRALGRAIL
D
Dimensione
5,5B USD
Margine
-243,8%
PSNLPersonalis
D
Dimensione
1,7B USD
Margine
-147,7%

Che cosa vende6

MI Profile
A cancer tissue test that examines DNA, RNA, and selected proteins, then gives doctors a report about the tumor that can help guide treatment choices.
Caris Assure
A blood test that examines tumor-related DNA and RNA in the blood and compares them with blood-cell DNA to help distinguish cancer changes from age-related blood-cell changes.
Caris Detect
A blood test designed to look for signs of multiple cancers, including cancers that may not yet have been found through symptoms or other tests.

Mostra altri 3

Caris ChromoSeq
A test of bone marrow or blood samples that examines DNA and RNA to help assess myeloid blood cancers, including acute myeloid leukemia and myelodysplastic syndromes.
Caris MI Clarity
A breast cancer test that examines digitized tissue-slide images and clinical information to estimate the chance of cancer returning at a distance from the original tumor.
FOLFIRSTai
A molecular signature included with certain cancer profiling results that helps doctors assess whether a patient with advanced colorectal cancer may benefit from particular chemotherapy combinations.

Chi lo compra4

Oncologists and other ordering physicians order tests for patients, often through hospitals, cancer centers, or medical groups.
Government and commercial health insurers pay for some patient tests when they cover the test and its use.
Biopharma companies pay for patient profiling, research support, and access to deidentified molecular and clinical data.
Academic cancer centers and researchers use Caris data and collaborate on cancer research.

Su cosa si regge e cosa potrebbe romperlo

Da che cosa dipende l'attività

1Most revenue comes from clinical molecular profiling, particularly tissue-based profiling.
2Clinical testing revenue depends on government and commercial insurers covering tests and setting reimbursement rates; Medicare-covered cases generated 40.0% (six months ended June 30, 2026, high) of molecular profiling services revenue.
3Laboratory work relies on sequencing equipment and supplies from third-party suppliers, including Illumina and Roche.
4The company depends on laboratory capacity, sample transport and handling, and computing systems to process patient samples and deliver results.

Che cosa potrebbe andare storto

1A large share of current revenue comes from tissue-based profiling, so changes in test volumes or physician and patient adoption could affect the business.
2Insurers and government programs decide whether to cover tests and how much to reimburse; limited coverage or lower reimbursement could constrain testing and revenue.
3New and developing tests depend on validation, regulatory requirements, and payer decisions; delays or changes in these areas could prevent or limit their commercial use.

Bilanci completi →

Informazioni su Caris Life Sciences, Inc.

Sede: Irving, Texas
Fondata nel: 2008
Quotata su: Nasdaq
Chiusura dell'esercizio: December 31

Come guadagna

Compete con

Che cosa vende6

Chi lo compra4

Su cosa si regge e cosa potrebbe romperlo

Da che cosa dipende l'attività

Che cosa potrebbe andare storto

Informazioni su Caris Life Sciences, Inc.

Keep exploring

Highest-graded in Biotechnology

Grade rose recently in Healthcare

Come guadagna

Compete con

Che cosa vende6

Chi lo compra4

Su cosa si regge e cosa potrebbe romperlo

Da che cosa dipende l'attività

Che cosa potrebbe andare storto

Informazioni su Caris Life Sciences, Inc.

Keep exploring

Highest-graded in Biotechnology

Grade rose recently in Healthcare

Caris Life Sciences, Inc.

Q3 2026 results

Revenue

EPS, GAAP

Operating income, GAAP

Company outlook

Crescita e cassa — 5 su 5

Andamento dell'attività

Prezzo dell’azione e voto nel tempo

Come guadagna

Compete con

Che cosa vende6

Chi lo compra4

Su cosa si regge e cosa potrebbe romperlo

Da che cosa dipende l'attività

Che cosa potrebbe andare storto

Informazioni su Caris Life Sciences, Inc.

Keep exploring

Highest-graded in Biotechnology

Grade rose recently in Healthcare

Come guadagna

Compete con

Che cosa vende6

Chi lo compra4

Su cosa si regge e cosa potrebbe romperlo

Da che cosa dipende l'attività

Che cosa potrebbe andare storto

Informazioni su Caris Life Sciences, Inc.

Keep exploring

Highest-graded in Biotechnology

Grade rose recently in Healthcare

Caris Life Sciences, Inc.

Andamento passato

Q3 2026 results

Revenue

EPS, GAAP

Operating income, GAAP

Company outlook

Crescita e cassa — 5 su 5

Andamento dell'attività

Prezzo dell’azione e voto nel tempo